Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20340484 | 0.89 | SMN1; SMN2 (0.66) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL18199495 | 0.89 | SMN1; SMN2 (0.66) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL607172 | 0.86 | TP53 (0.53) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL18908668 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL7325345 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL10088093 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL26442666 | 0.82 | DNM1 (0.54) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL24692521 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL7035049 | 0.81 | CASP2 (0.59) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL20695624 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20210206779-A9 | CYANO THIENOTRIAZOLODIAZEPINES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20200407371-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200199150-A1 | CYANO THIENOTRIAZOLODIAZEPINES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-8372597-B2 | Methods of screening for introduction of DNA into a target cell | XENOGEN CORPORATION (US) | 2013-02-12 | — | — | US | disclosed |
| EP-1390744-B1 | ISOLATION AND IDENTIFICATION OF MOUSE AND HUMAN TRANSCRIPTION CONTROL ELEMENTS ASSOCIATED WITH CYTOCHROME EXPRESSION | XENOGEN CORP (US) | 2012-09-26 | — | — | EP | disclosed |
| US-7449567-B2 | Isolation and identification of mouse and human transcription control elements associated with cytochrome expression | XENOGEN CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070010018-A1 | Methods of screening for introduction of DNA into a target cell | FRANCIS KEVIN P | 2007-01-11 | — | — | US | disclosed |
| US-7115793-B2 | Isolation and identification of transcription control elements associated with mouse eosinophil peroxidase expression | XENOGEN CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| US-7090994-B2 | Methods of screening for introduction of DNA into a target cell | XENOGEN CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-6858773-B2 | Transgenic mice comprising transcription control elements associated with mouse eosinophil peroxidase expression | XENOGEN CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1390744-A2 | ISOLATION AND IDENTIFICATION OF MOUSE AND HUMAN TRANSCRIPTION CONTROL ELEMENTS ASSOCIATED WITH CYTOCHROME EXPRESSION | Xenogen Corporation (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1373481-A1 | METHODS OF SCREENING FOR INTRODUCTION OF DNA INTO A TARGET CELL | Xenogen Corporation (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030145341-A1 | Isolation and identification of mouse and human transcription control elements associated with cytochrome expression | XENOGEN CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-20030135871-A1 | Modified railroad worm red luciferase coding sequences | XENOGEN CORPORATION | 2003-07-17 | — | — | US | disclosed |
| WO-2003016839-A2 | MODIFIED RAILROAD WORM RED LUCIFERASE CODING SEQUENCES | XENOGEN CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| US-20030005472-A1 | Isolation and identification of transcription control elements associated with mouse eosinophil peroxidase expression | XENOGEN CORPORATION | 2003-01-02 | — | — | US | disclosed |
| US-20020192755-A1 | Methods of screening for introduction of DNA into a target cell | XENOGEN CORPORATION | 2002-12-19 | — | — | US | disclosed |
| WO-2002088305-A2 | ISOLATION AND IDENTIFICATION OF MOUSE AND HUMAN TRANSCRIPTION CONTROL ELEMENTS ASSOCIATED WITH CYTOCHROME EXPRESSION | XENOGEN CORPORATION (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002072808-A1 | METHODS OF SCREENING FOR INTRODUCTION OF DNA INTO A TARGET CELL | XENOGEN CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206779-A9 | CYANO THIENOTRIAZOLODIAZEPINES AND USES THEREOF | BRDT, BRD4, BRD3 | SMN1; SMN2 4697/4885TP53 1072/4885ALDH1A1 4304/4885 |
| US-20200407371-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | BAZ2A, BRD3, BRPF3 | SMN1; SMN2 3849/4885TP53 345/4885ALDH1A1 4164/4885 |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | BAZ2A, BRD3, BRPF3 | SMN1; SMN2 3849/4885TP53 345/4885ALDH1A1 4164/4885 |
| US-20200199150-A1 | CYANO THIENOTRIAZOLODIAZEPINES AND USES THEREOF | BRDT, BRD4, BRD3 | SMN1; SMN2 4697/4885TP53 1072/4885ALDH1A1 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.